Paragon (ANZGOG-0903): phase 2 study of Anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer

- Bonaventura, Anthony, O'Connell, Rachel L., Martyn, Julie, DeFazio, Anna, Scurry, James, Friedlander, Michael L., Mapagu, Cristina, Beale, Philip J., McNally, Orla M., Mileshkin, Linda R., Grant, Peter T., Hadley, Alison M., Goh, Jeffery C. H., Sjoquist, Katrin M.

The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)

- Matz, Melissa, Coleman, Michel P., Sant, Milena, Chirlaque, Maria Dolores, Visser, Otto, Gore, Martin, Allemani, Claudia, CONCORD Working Group,, Martin, J.

The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

- Strumidło, Agnieszka, Skiba, Sylwia, Scott, Rodney J., Lubiński, Jan

Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2)

- Matz, Melissa, Coleman, Michel P., Carreira, Helena, Salmerón, Diego, Chirlaque, Maria Dolores, Allemani, Claudia, CONCORD Working Group, Martin, J.

Genetic changes correlate with histopathology in a benign, borderline and malignant mucinous ovarian tumour

- Bowden, N. A., Smyth, M., Jaaback, K., Ashton, K. A., Scurry, J.

Ovarian hormones through Wnt signalling regulate the growth of human and mouse ovarian cancer initiating lesions

- Nagendra, Prathima B., Goad, Jyoti, Nielsen, Sarah, Rassam, Loui, Lombard, Janine M., Nahar, Pravin, Tanwar, Pradeep S.

RAD51B in familial breast cancer

- Pelttari, Liisa M., Khan, Sofia, Dörk, Thilo, Forbes, John, Bogdanova, Natalia V., Figueroa, Jonine, Pharoah, Paul D. P., Schmidt, Marjanka K., Dunning, Alison M., García-Closas, Montserrat, Bolla, Manjeet K., Dennis, Joe, Michailidou, Kyriaki, Vuorela, Mikko, Wang, Qin, Hopper, JL, Southey, MC, Rosenberg, EH, Fasching, PA, Beckmann, MW, Peto, J, Dos-Santos-silva, I, Sawyer, EJ, Tomlinson, I, Kiiski, Johanna I., Burwinkel, B, Surowy, H, Guénel, P, Truong, T, Bojesen, SE, Nordestgaard, BG, Benitez, J, González-Neira, A, Neuhausen, SL, Anton-Culver, H, Vilske, Sara, Brenner, H, Arndt, V, Meindl, A, Schmutzler, RK, Brauch, H, Brüning, T, Lindblom, A, Margolin, S, Mannermaa, A, Hartikainen, JM, Nevanlinna, Viivi, Chenevix-Trench, G, Van Dyck, L, Janssen, H, Chang-Claude, J, Rudolph, A, Radice, P, Peterlongo, P, Hallberg, E, Olson, JE, Giles, GG, Ranta, Salla, Milne, RL, Haiman, CA, Schumacher, F, Simard, J, Dumont, M, Kristensen, V, Borresen-Dale, AL, Zheng, W, Beeghly-Fadiel, A, Grip, M, Schleutker, Johanna, Andrulis, IL, Glendon, G, Devilee, P, Seynaeve, C, Hooning, MJ, Collée, M, Cox, A, Cross, SS, Shah, M, Luben, RN, Winqvist, Robert, Hamann, U, Torres, D, Jakubowska, A, Lubinski, J, Couch, FJ, Yannoukakos, D, Orr, N, Swerdlow, A, Darabi, H, Li, J, Kallioniemi, Anne, Czene, K, Hall, P, Easton, DF, Mattson, J, Blomqvist, C, Aittomäki, K, Nevanlinna, H, Aghmesheh, M, Amor, D, Andrews, L

Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model

- Noorani, Lubna, Stenzel, Martina, Liang, Roger, Pourgholami, Mohammad H., Morris, David L.

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer

- Moran-Jones, Kim, Gloss, Brian S., Spong, Suzanne M., Scarlett, Christopher J., Hacker, Neville F., Ghosh, Sue, Mok, Samuel C., Birrer, Michael J., Samimi, Goli, Murali, Rajmohan, Chang, David K., Colvin, Emily K., Jones, Marc D., Yuen, Samuel, Howell, Viive M., Brown, Laura M., Wong, Carol W.

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families

- Dębniak, Tadeusz, Gromowski, Tomasz, Cybulski, Cezary, Serrano-Fernandez, Pablo, Lubiński, Jan, Scott, Rodney J., Gronwald, Jacek, Huzarski, Tomasz, Byrski, Tomasz, Kurzawski, Grzegorz, Dymerska, Dagmara, Górski, Bohdan, Paszkowska-Szczur, Katarzyna

Albendazole loaded albumin nanoparticles for ovarian cancer therapy

- Noorani, Lubna, Pourgholami, Mohammad Hossein, Liang, Mingtao, Morris, David Lawson, Stenzel, Martina

First recurrent large genomic rearrangement in the BRCA1 gene found in Poland

- Rudnicka, Helena, Masojc, Bartlomiej, van de Wetering, Thierry, Debniak, Tadeusz, Cybulski, Cezary, Gronwald, Jacek, Lubinski, Jan, Gorski, Bohdan, Scott, Rodney

Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer

- Tanwar, Pradeep S., Mohapatra, Gayatry, Chiang, Sarah, Engler, David A., Zhang, LiHua, Kaneko-Tarui, Tomoko, Ohguchi, Yasuyo, Birrer, Michael J., Teixeira, Jose M.

Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?

- Bowden, Nikola A.

PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression

- Tanwar, Pradeep S., Kaneko-Tarui, Tomoko, Lee, Ho-Joon, Zhang, LiHua, Teixeira, Jose M.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients

- Jacob, Francis, Ukegjini, Kristjan, Fink, Daniel A., Hacker, Neville F., Heinzelmann-Schwarz, Viola A., Nixdorf, Sheri, Ford, Caroline E., Olivier, Jake, Caduff, Rosmarie, Scurry, James P., Guertler, Rea, Hornung, Daniela, Mueller, Renato

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer

- Montavon, Céline, Gloss, Brian S., Hacker, Neville .F, Sutherland, Robert L., Clark, Susan J., O'Brien, Philippa M., Warton, Kristina, Barton, Caroline A., Statham, Aaron L., Scurry, James P., Tabor, Bruce, Nguyen, Tuan V., Qu, Wenja, Samimi, Goli

BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms

- Jakubowska, Anna, Gronwald, Jacek, Eils, Roland, Lubińki, Jan, Scott, Rodney J., Hamann, Ute, Menkiszak, Janusz, Górski, Bohdan, Huzarski, Tomasz, Byrski, Tomasz, Toloczko-Grabarek, Aleksandra, Gilbert, Michael, Edler, Lutz, Zapatka, Marc

Risk Malignancy Index (RMI) in patients with abnormal pelvic mass: comparing RMI 1, 2 and 3 in an Australian population

- Kader Ali Mohan, Ganendra Raj, Jaaback, Kenneth, Proietto, Anthony, Robertson, Randall, Angstetra, Donald

Reducing inequities in cancer care: the role of cancer registries

- Sanson-Fisher, Rob, Carey, Mariko, Mackenzie, Lisa, Hill, David, Campbell, Sharon, Turner, Donna